Last reviewed · How we verify
Efmoroctocog Alfa Injection [Eloctate]
Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients.
Efmoroctocog alfa is a recombinant human coagulation factor VIII fused to human serum albumin, which replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients. Used for Hemophilia A (congenital factor VIII deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.
At a glance
| Generic name | Efmoroctocog Alfa Injection [Eloctate] |
|---|---|
| Sponsor | The League of Clinical Research, Russia |
| Drug class | Recombinant coagulation factor VIII |
| Target | Coagulation factor VIII (intrinsic tenase complex) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
This fusion protein combines factor VIII (the missing or deficient clotting factor in hemophilia A) with human serum albumin, which extends the half-life of factor VIII in circulation. By providing functional factor VIII, the drug restores the intrinsic coagulation pathway and enables normal blood clot formation, reducing spontaneous and trauma-induced bleeding episodes.
Approved indications
- Hemophilia A (congenital factor VIII deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes
Common side effects
- Inhibitor development (anti-factor VIII antibodies)
- Injection site reactions
- Headache
- Fever
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: